Crispr Therapeutics AG (CRSPN) Ratios
Crispr Therapeutics AG Ratios
MX:CRSPN's free cash flow for Q2 2026 was $-86.62M. For the 2026 fiscal year, MX:CRSPN's free cash flow was decreased by $-3.12M and operating cash flow was $-83.50M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 |
| Quick Ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 |
| Cash Ratio | 2.38 | 3.40 | 3.58 | 1.75 | 7.70 |
| Solvency Ratio | -1.64 | -1.12 | -0.39 | -1.70 | 1.12 |
| Operating Cash Flow Ratio | -2.31 | -1.63 | -2.39 | -4.09 | 4.50 |
| Short-Term Operating Cash Flow Coverage | -18.57 | -8.26 | -16.66 | -31.29 | 44.33 |
| Net Current Asset Value | $ 1.64B | $ 1.63B | $ 1.56B | $ 1.49B | $ 2.07B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.10 | 0.11 | 0.11 | 0.08 |
| Debt-to-Equity Ratio | 0.21 | 0.12 | 0.13 | 0.13 | 0.09 |
| Debt-to-Capital Ratio | 0.17 | 0.10 | 0.11 | 0.12 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.18 | 1.16 | 1.18 | 1.20 | 1.15 |
| Debt Service Coverage Ratio | -30.26 | -20.07 | -13.16 | -40.95 | 32.05 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.04 | 0.01 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 4.39 | 2.65 | 3.01 | 3.14 | 2.96 |
| Net Debt to EBITDA | -0.07 | 0.22 | 0.74 | -0.05 | -1.78 |
| Profitability Margins | |||||
| Gross Profit Margin | -6537.01% | -215.00% | 64.80% | -25186.70% | 88.92% |
| EBIT Margin | -16466.24% | -1036.19% | -60.15% | -154394.72% | 40.91% |
| EBITDA Margin | -15911.28% | -981.16% | -54.78% | -148850.69% | 42.87% |
| Operating Profit Margin | -16191.40% | -1333.05% | -60.15% | -154394.72% | 40.91% |
| Pretax Profit Margin | -16466.24% | -1036.19% | -40.74% | -149197.25% | 41.57% |
| Net Profit Margin | -16569.77% | -1046.43% | -41.52% | -149122.71% | 41.36% |
| Continuous Operations Profit Margin | -16569.77% | -1046.43% | -41.52% | -149122.71% | 41.36% |
| Net Income Per EBT | 100.63% | 100.99% | 101.92% | 99.95% | 99.51% |
| EBT Per EBIT | 101.70% | 77.73% | 67.73% | 96.63% | 101.61% |
| Return on Assets (ROA) | -25.67% | -16.34% | -6.89% | -28.99% | 13.72% |
| Return on Equity (ROE) | -30.26% | -18.96% | -8.16% | -34.67% | 15.74% |
| Return on Capital Employed (ROCE) | -26.86% | -21.66% | -10.49% | -31.72% | 14.19% |
| Return on Invested Capital (ROIC) | -26.62% | -21.49% | -10.42% | -31.47% | 14.06% |
| Return on Tangible Assets | -25.67% | -16.34% | -6.89% | -28.99% | 13.72% |
| Earnings Yield | -12.33% | -11.03% | -3.10% | -20.57% | 6.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 1.40 | 1.85 | 0.00 | 2993.71 |
| Payables Turnover | 20.92 | 7.50 | 3.41 | 4.02 | 6.83 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.01 | 0.13 | 1.21 | 0.00 | 2.93 |
| Asset Turnover | 0.00 | 0.02 | 0.17 | 0.00 | 0.33 |
| Working Capital Turnover Ratio | 0.00 | 0.02 | 0.21 | 0.00 | 0.47 |
| Cash Conversion Cycle | -17.45 | 212.02 | 90.40 | -90.80 | -53.33 |
| Days of Sales Outstanding | 0.00 | 260.71 | 197.30 | 0.00 | 0.12 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 17.45 | 48.70 | 106.90 | 90.80 | 53.45 |
| Operating Cycle | 0.00 | 260.71 | 197.30 | 0.00 | 0.12 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.84 | -1.69 | -3.29 | -6.38 | 7.10 |
| Free Cash Flow Per Share | -3.85 | -1.71 | -3.41 | -6.85 | 6.02 |
| Dividend Paid and CapEx Coverage Ratio | -377.48 | -75.10 | -27.49 | -13.33 | 6.60 |
| Capital Expenditure Coverage Ratio | -377.48 | -75.10 | -27.49 | -13.33 | 6.60 |
| Operating Cash Flow Coverage Ratio | -0.87 | -0.64 | -1.09 | -2.03 | 2.40 |
| Operating Cash Flow to Sales Ratio | -98.29 | -4.08 | -0.70 | -1137.02 | 0.59 |
| Free Cash Flow Yield | -7.34% | -4.36% | -5.44% | -16.86% | 7.95% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.11 | -9.07 | -32.28 | -4.86 | 15.24 |
| Price-to-Sales (P/S) Ratio | 1343.50 | 94.87 | 13.40 | 7248.62 | 6.30 |
| Price-to-Book (P/B) Ratio | 2.45 | 1.72 | 2.63 | 1.69 | 2.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.63 | -22.95 | -18.38 | -5.93 | 12.59 |
| Price-to-Operating Cash Flow Ratio | -13.67 | -23.26 | -19.05 | -6.38 | 10.68 |
| Price-to-Earnings Growth (PEG) Ratio | -0.17 | -0.07 | 0.42 | 0.02 | -0.08 |
| Enterprise Value Multiple | -8.51 | -9.45 | -23.72 | -4.92 | 12.92 |
| Enterprise Value | 4.76B | 3.25B | 4.81B | 3.19B | 5.06B |
| EV to EBITDA | -8.51 | -9.45 | -23.72 | -4.92 | 12.92 |
| EV to Sales | 1354.81 | 92.74 | 13.00 | 7322.33 | 5.54 |
| EV to Free Cash Flow | -13.75 | -22.44 | -17.82 | -5.99 | 11.06 |
| EV to Operating Cash Flow | -13.78 | -22.73 | -18.47 | -6.44 | 9.38 |
| Tangible Book Value Per Share | 21.37 | 22.90 | 23.77 | 24.12 | 31.59 |
| Shareholders’ Equity Per Share | 21.37 | 22.90 | 23.77 | 24.12 | 31.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 |
| Revenue Per Share | 0.04 | 0.41 | 4.67 | 0.01 | 12.02 |
| Net Income Per Share | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 |
| Tax Burden | 1.01 | 1.01 | 1.02 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.68 | 0.97 | 1.02 |
| Research & Development to Revenue | 75.59 | 9.16 | 1.05 | 1058.82 | 0.37 |
| SG&A to Revenue | 20.95 | 2.09 | 0.21 | 235.01 | 0.11 |
| Stock-Based Compensation to Revenue | 20.65 | 2.47 | 0.22 | 224.65 | 0.11 |
| Income Quality | 0.59 | 0.39 | 1.70 | 0.76 | 1.43 |
Currency in USD
